Anebulo Pharmaceuticals (ANEB) Accounts Payables (2021 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Accounts Payables of $554862.0 for Q4 2025, up 73.66% year-over-year from $319515.0 in Q4 2024, and down 8.67% quarter-over-quarter from $607539.0 in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Accounts Payables (2021 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Accounts Payables for 5 consecutive years, with $554862.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Accounts Payables rose 73.66% year-over-year to $554862.0; the TTM figure through Dec 2025 stood at $554862.0 (up 73.66% YoY), while the FY2025 annual figure was $224175.0, up 43.31% from the prior year.
- Accounts Payables fell to $554862.0 in Q4 2025 per ANEB's latest filing, from $607539.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $607539.0 in Q3 2025 and bottomed at $42944.0 in Q4 2021.
- Historically, Accounts Payables has averaged $349010.1 across 5 years, with a median of $363691.0 in 2022.
- Annual changes were most pronounced in 2022 — Accounts Payables soared 706.99% — and 2024, when it sank 70.74%.
- Anebulo Pharmaceuticals' Accounts Payables stood at $42944.0 in 2021, then soared by 706.99% to $346554.0 in 2022, then fell by 8.04% to $318679.0 in 2023, then advanced by 0.26% to $319515.0 in 2024, then jumped by 73.66% to $554862.0 in 2025.
- Business Quant data shows ANEB's Accounts Payables at $554862.0 in Q4 2025, $607539.0 in Q3 2025, and $224175.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 35.57 Mn |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | 554,862.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 554,862.00 |
| Sep 30, 2025 | 607,539.00 |
| Jun 30, 2025 | 224,175.00 |
| Mar 31, 2025 | 427,578.00 |
| Dec 31, 2024 | 319,515.00 |
| Sep 30, 2024 | 252,142.00 |
| Jun 30, 2024 | 156,426.00 |
| Mar 31, 2024 | 384,920.00 |
| Dec 31, 2023 | 318,679.00 |
| Sep 30, 2023 | 565,949.00 |
| Jun 30, 2023 | 534,545.00 |
| Mar 31, 2023 | 570,902.00 |
| Dec 31, 2022 | 346,554.00 |
| Sep 30, 2022 | 523,473.00 |
| Jun 30, 2022 | 380,828.00 |
| Mar 31, 2022 | 83,277.00 |
| Dec 31, 2021 | 42,944.00 |
| Sep 30, 2021 | 493,819.00 |
| Jun 30, 2021 | 110,048.00 |
| Mar 31, 2021 | 82,027.00 |